Compare FENG & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FENG | OSRH |
|---|---|---|
| Founded | 1998 | N/A |
| Country | China | United States |
| Employees | N/A | 22 |
| Industry | Broadcasting | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2M | 17.9M |
| IPO Year | 2011 | N/A |
| Metric | FENG | OSRH |
|---|---|---|
| Price | $1.56 | $0.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.8K | ★ 928.1K |
| Earning Date | 05-12-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.53 | $0.37 |
| 52 Week High | $3.65 | $1.57 |
| Indicator | FENG | OSRH |
|---|---|---|
| Relative Strength Index (RSI) | 39.28 | 36.15 |
| Support Level | N/A | N/A |
| Resistance Level | $1.82 | $0.45 |
| Average True Range (ATR) | 0.06 | 0.03 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 12.50 | 2.42 |
Phoenix New Media Ltd is a media company providing premium content on an integrated platform across the internet, mobile and TV channels in China. The company organizes its operations into two main segments: Net advertising services and Paid services. It provides its content and services through three channels: ifeng.com channel, video channel, and mobile channel. The company also offers a wide range of paid services including mobile value-added services, games, and content sales. It generates the majority of its revenue from Net advertising services. Geographically, it derives all of its revenue from PRC.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea. The company's pipeline products include: Vaximm, Darnatein, Woori IO, and RMC.